+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
End Stage Renal Disease Market - Global Forecast 2026-2032- Product Image
End Stage Renal Disease Market - Global Forecast 2026-2032- Product Image
New

End Stage Renal Disease Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 190 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337854
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The end stage renal disease market is evolving, fueled by clinical breakthroughs, digital innovation, and regulatory shifts. Senior leaders face emerging opportunities as treatment modalities diversify and value-based models reshape care delivery across regions.

Market Snapshot: End Stage Renal Disease Market

The end stage renal disease market is poised for significant expansion, with revenues projected to grow from USD 61.04 billion in 2025 to USD 70.18 billion in 2026. This trajectory is expected to continue, driven by a compound annual growth rate (CAGR) of 15.26%, reaching total market value of USD 164.97 billion by 2032.

Scope & Segmentation

  • Treatment Modalities: The market covers a wide array of therapies including hemodialysis (available in-center and for home use), peritoneal dialysis (both continuous ambulatory and continuous cycling), as well as transplantation from deceased and living donors. Each modality necessitates distinct clinical protocols and infrastructure, impacting operational models and procurement.
  • Access Types: Decision-makers must consider options such as arteriovenous fistula, central venous catheter, and synthetic graft. Each type involves unique workflow implications and procurement considerations, influencing continuity of care and supply chain requirements.
  • End-User Settings: Settings span dialysis centers, home care, and hospitals, each demanding tailored supply chains and management strategies. Adapting operational practices to the specific needs of these entities supports overall system resilience and patient continuity.
  • Technologies: New advancements include portable dialysis machines, remote monitoring solutions, digital therapeutics for patient engagement, improvements in vascular access, and telemedicine-driven clinician training. These technologies streamline operations and enable new care models at both facility and remote sites.
  • Regions Covered: The scope encompasses the Americas, Europe, Middle East & Africa, and Asia-Pacific. Each region demonstrates different levels of healthcare infrastructure, procurement complexity, and payer frameworks, significantly affecting market adoption, policy implementation, and supply chain planning.

Key Takeaways for Senior Leaders

  • Innovation in equipment and monitoring fosters transition towards home-based dialysis, expanding patient choice and decentralizing care delivery.
  • Policy and regulatory developments prompt changes in site-of-care decisions, encouraging adoption of bundled models and greater awareness of care pathway costs.
  • Supply chain vulnerabilities, notably in light of recent tariff measures, necessitate shifts toward localized manufacturing, diversified sourcing, and robust inventory strategies to ensure continuity.
  • Differentiation in clinical settings and treatment pathways calls for targeted commercial and evidentiary approaches, adjusting go-to-market strategies to each environment.
  • Advanced digital platforms enable predictive analytics and real-time clinical oversight, supporting improved adherence and operational performance.
  • Regional disparities shape the feasibility and pace of technology adoption, underlining the importance of adaptable rollouts and context-specific implementation plans to achieve penetration across diverse healthcare structures.

Tariff Impact

The implementation of tariff measures in 2025 significantly affected market dynamics by increasing the cost of imported dialysis components and consumables. In response, industry stakeholders revised sourcing approaches, established new supplier agreements, and prioritized relationships with domestic or vertically aligned vendors. This rapid adjustment accelerated efforts toward diversification and nearshoring, reinforcing supply chain resilience. Healthcare providers also modified procurement strategies to safeguard essential clinical service continuity during periods of disruption, with a greater focus placed on evaluating total lifecycle costs rather than upfront expenses alone.

Methodology & Data Sources

This report adopts a triangulated research approach, drawing on structured interviews with clinicians, procurement specialists, and engineers, supplemented by expert panel validation. The analysis integrates secondary sources including peer-reviewed publications, regulatory materials, and policy documents. Findings are synthesized using thematic coding and scenario planning, with all outputs cross-verified for accuracy and dependability.

Why This Report Matters

  • Connects clinical advancements and technology developments with commercial decision frameworks, enabling executive teams to refine investment and partnership priorities.
  • Clarifies regulatory and supply chain disruptions, supporting the formulation of resilient procurement and deployment strategies.
  • Delivers segmentation insights to support competitive positioning in an increasingly diverse treatment environment.

Conclusion

Continuous innovation, complex supply chains, and evolving care models define the future of end stage renal disease care. Data-driven, flexible strategies are critical for achieving quality clinical outcomes and maintaining competitive standing within this dynamic market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. End Stage Renal Disease Market, by Treatment Modality
8.1. Hemodialysis
8.1.1. Home
8.1.2. Incenter
8.2. Peritoneal Dialysis
8.2.1. Continuous Ambulatory Peritoneal Dialysis
8.2.2. Continuous Cycling Peritoneal Dialysis
8.3. Transplant
8.3.1. Deceased Donor
8.3.2. Living Donor
9. End Stage Renal Disease Market, by Access Type
9.1. Arteriovenous Fistula
9.2. Central Venous Catheter
9.3. Synthetic Graft
10. End Stage Renal Disease Market, by End User
10.1. Dialysis Centers
10.2. Home Care Settings
10.3. Hospitals
11. End Stage Renal Disease Market, by Region
11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific
12. End Stage Renal Disease Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. End Stage Renal Disease Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. United States End Stage Renal Disease Market
15. China End Stage Renal Disease Market
16. Competitive Landscape
16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. AngioDynamics Inc.
16.6. Asahi Kasei Corporation
16.7. B. Braun Melsungen AG
16.8. Baxter International Inc.
16.9. Cantel Medical Corp.
16.10. DaVita Inc.
16.11. Dialysis Clinic Inc.
16.12. Fresenius Medical Care AG & Co. KGaA
16.13. Medtronic plc
16.14. Nipro Corporation
16.15. NxStage Medical Inc.
16.16. Outset Medical Inc.
16.17. Rockwell Medical Inc.
16.18. Satellite Healthcare Inc.
16.19. U.S. Renal Care Inc.
List of Figures
FIGURE 1. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 84. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 85. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 86. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 87. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 88. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 98. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 99. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 100. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 101. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 102. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 113. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 114. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 115. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 116. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 117. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 120. GCC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 121. GCC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 122. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 123. GCC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 124. GCC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 134. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 135. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 136. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 137. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 138. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 141. G7 END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 142. G7 END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 143. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 144. G7 END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 145. G7 END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 148. NATO END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 149. NATO END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 150. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 151. NATO END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 152. NATO END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. CHINA END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 162. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 163. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
TABLE 164. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
TABLE 165. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 166. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
TABLE 167. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this End Stage Renal Disease market report include:
  • AngioDynamics Inc.
  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Cantel Medical Corp.
  • DaVita Inc.
  • Dialysis Clinic Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Medtronic plc
  • Nipro Corporation
  • NxStage Medical Inc.
  • Outset Medical Inc.
  • Rockwell Medical Inc.
  • Satellite Healthcare Inc.
  • U.S. Renal Care Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 70.18 Billion
Forecasted Market Value ( USD ) by 2032 $ 164.97 Billion
Compound Annual Growth Rate15.2%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

End-stage Renal Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

End-stage Renal Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
End-Stage Renal Disease - Global Strategic Business Report - Product Image

End-Stage Renal Disease - Global Strategic Business Report

  • Report
  • 174 Pages
  • Global
From
End Stage Renal Disease Drug Pipeline Analysis Report 2025 - Product Image

End Stage Renal Disease Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
End-Stage Kidney Disease - Pipeline Insight, 2025 - Product Image

End-Stage Kidney Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Chronic Kidney Disease Market - Global Forecast 2026-2032 - Product Image

Chronic Kidney Disease Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From

About the End Stage Renal Disease Drug Market

End Stage Renal Disease (ESRD) Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. ESRD drugs are used to treat patients with advanced kidney failure, who require dialysis or a kidney transplant. These drugs are used to reduce the symptoms of kidney failure, such as anemia, high blood pressure, and bone disease. They also help to reduce the risk of complications from dialysis and kidney transplantation. Common ESRD drugs include erythropoietin, calcitriol, and iron supplements. The ESRD Drug market is highly competitive, with many companies offering a variety of products. Major players in the market include Amgen, AstraZeneca, Baxter, Fresenius Medical Care, and Novartis. Other companies in the market include AbbVie, Allergan, Daiichi Sankyo, and Merck. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.